Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer Inc. closed 25.65% short of its 52-week high of $31.54, which the company achieved on July 30th.

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Last year was a strong year in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to the decline in revenues and profits. It saw improved performance of its ...

Shares of Pfizer Inc. PFE slid 1.82% to $23.18 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.56% to 5,888.55 and Dow ...

It compares these trends to the stock’s performance during the 2008 recession. In contrast, here’s how PFE stock and the broader market performed during the 2007/2008 crisis. PFE stock ...

MRNA stock Vs. PFE stock YTD performance (as of 31 Aug 21). Therefore, with both companies having their fair share of success in the COVID-19 market, we are rather surprised (although as MRNA ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...